Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review
2011

Immunotherapy for Colorectal Cancer: A Meta-Analysis

Sample size: 2031 publication 10 minutes Evidence: moderate

Author Information

Author(s): Rao Benqiang, Han Minyan, Wang Lei, Gao Xiaoyan, Huang Jun, Huang Meijin, Liu Huanliang, Wang Jianping

Primary Institution: The Sixth Affiliated Hospital, Sun Yat-sen University

Hypothesis

Does active specific immunotherapy (ASI) improve clinical outcomes in advanced colorectal cancer and suspected minimal residual colorectal cancer?

Conclusion

ASI shows promising clinical responses in patients with suspected minimal residual colorectal cancer, but limited effectiveness in advanced colorectal cancer.

Supporting Evidence

  • 1375 patients with suspected minimal residual CRC showed improved overall survival with ASI.
  • Statistical significance was achieved for disease-free survival in stage III suspected minimal residual CRC.
  • Only 1.68% of advanced CRC patients showed clinical responses to ASI.

Takeaway

This study looked at how a special treatment called immunotherapy helps people with colorectal cancer. It found that it works better for some patients who might still have small amounts of cancer left after surgery.

Methodology

A meta-analysis of studies on ASI in colorectal cancer was conducted, focusing on overall survival and disease-free survival.

Potential Biases

Some studies had unclear randomization and allocation concealment, leading to potential bias.

Limitations

The study included only human trials published in English and excluded case studies and studies with fewer than three patients.

Participant Demographics

The study involved 2031 patients, with 1375 in the suspected minimal residual CRC group and 656 in the advanced CRC group.

Statistical Information

P-Value

0.007

Confidence Interval

0.63-0.93

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1479-5876-9-17

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication